Company / Cash & Equivalents
Neuronetics, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$28.1M
FY2025
5-year range
$28.1M / $94.1M
FY2021-FY2025
Trend
-52.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $70M to $28M over the past 2 years.
Based on SEC 10-K filings.
$28M in FY2025 with a 5-year CAGR of -10.5%.
Declined from $70M to $28M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -26.3%
- 5-Year CAGR
- -10.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 52.9% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.07 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.1M | -52.9% |
| FY2024 | $59.7M | -15.2% |
| FY2023 | $70.3M | +0.0% |
| FY2022 | $70.3M | -25.3% |
| FY2021 | $94.1M | +92.3% |
| FY2020 | $49.0M | -35.3% |
| FY2019 | $75.7M | -27.6% |
| FY2018 | $104.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026